• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Senores Pharmaceuticals Ltd.
    12 Mar 2025
    Insider Trades
    690.15
    -1.12%
    Senores Pharma up 4% as board approves acquisition of 3.73% stake in Havix
    Business Standard
    Post the acquisition, the shareholding of Senores Pharma in Havix will increase to 54.96 per cent
    Copy LinkShare onShare on Share on Share on
    Senores Pharmaceuticals Ltd. has gained 76.51% in the last 1 Year
    logo
    Glenmark Pharmaceuticals Ltd.
    12 Mar 2025
    1923.90
    -0.67%
    Glenmark launches Empagliflozin for diabetes in India under Glempa brand
    Business Standard
    Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes patients. The Mumbai-based drug firm has launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'?Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk. Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, supporting weight-loss, and reducing cardiovascular-renal risks in patients with type 2 diabetes mellitus. Empagliflozin has also demonstrated benefits in heart failure patients by lowering the cardiovascular death or hospitalisation. "The launch of Glempa range ..
    Copy LinkShare onShare on Share on Share on
    Glenmark Pharmaceuticals Ltd. is trading above its 200 day SMA of 1601.9
    logo
    Alkem Laboratories Ltd.
    12 Mar 2025
    5303.50
    -1.35%
    Alkem launches low-cost diabetes drug in Indian market
    Business Line
    The company is introducing several combination therapies including Empanorm L (empagliflozin and linagliptin), Empanorm Duo and Alsita E (empagliflozin and sitagliptin), and Empanorm M (empagliflozin and metformin)
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.
    logo
    Pfizer Ltd.
    11 Mar 2025
    5156.00
    -0.23%
    Pfizer's breast cancer drug Vepdegestrant posts mixed results in key trial
    Business Standard
    The drug, vepdegestrant, failed to meaningfully delay cancer progression for all patients enrolled in the study but met its goals for a subset who have a specific genetic mutation
    Copy LinkShare onShare on Share on Share on
    Pfizer Ltd. has gained 27.31% in the last 6 Months
    logo
    Lupin Ltd.
    11 Mar 2025
    1894.90
    -0.39%
    Trump's tariff threat takes the sheen off Lupin's product launches
    Trump's tariff threat takes the sheen off Lupin's product launches
    livemint
    A big dampener to Lupin's plans would be the potential imposition of tariff on pharma products by the Trump government. However, the management expressed hope of an exemption for the pharma sector due to the risk of a shortage.
    Copy LinkShare onShare on Share on Share on
    Lupin Ltd. is trading below all available SMAs
    logo
    Emcure Pharmaceuticals Ltd.
    11 Mar 2025
    1393.40
    -2.68%
    Emcure Pharmaceuticals share gains on foraying into daily supplements space
    Business Standard
    The uptick in the Emcure Pharmaceuticals share price came after the company announced its entry into the daily supplements space with the expansion of its Arth range
    Copy LinkShare onShare on Share on Share on
    Emcure Pharmaceuticals Ltd. is trading above its 200 day SMA of 1245.0
    logo
    Sun Pharmaceutical Industries Ltd.
    11 Mar 2025
    1594.50
    0.55%
    'Buy' Sun Pharma Maintains Systematix, Sees Checkpoint Acquisition To Strengthen Onco Derma Portfolio
    'Buy' Sun Pharma Maintains Systematix, Sees Checkpoint Acquisition To Strengthen Onco Derma Portfolio
    NDTV Profit
    Systematix retains estimates on Sun Pharma and retain Buy with a target price of Rs 2,206 based on 35 times FY27E earnings per share.
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical Industries Ltd. is trading below all available SMAs
    Despite near term challenges, brokerages remain positive on Sun Pharma
    Business Standard | 11 Mar 2025
    logo
    Indoco Remedies Ltd.
    11 Mar 2025
    Dividend
    266.60
    -2.77%
    Here's why Indoco Remedies shares were under pressure on March 11; details
    Business Standard
    The fall in the share price came after the company announced that its Clinical Research Organisation, AnaCipher, located at Hyderabad, has received one Form 483 at the end of the inspection by USFDA
    Copy LinkShare onShare on Share on Share on
    Indoco Remedies Ltd. has gained 33.27% in the last 6 Months
    logo
    Syngene International Ltd.
    10 Mar 2025
    625.90
    -0.52%
    Syngene Buys US Manufacturing Plant In $50 Million Deal
    Syngene Buys US Manufacturing Plant In $50 Million Deal
    NDTV Profit
    The deal, which includes an upfront acquisition cost of $36.5 million, will also involve additional spending to make the facility operational.
    Copy LinkShare onShare on Share on Share on
    Syngene Internationa.. has an average target of 1030.00 from 1 broker.
    Syngene USA acquires its first manufacturing facility for $36.5 million
    Business Standard | 10 Mar 2025 2 more
    Syngene acquires first US biologics site for $50 mn to expand capacity
    Business Standard | 10 Mar 2025
    Syngene acquires first US facility from Emergent Manufacturing
    Business Line | 10 Mar 2025
    logo
    Sun Pharmaceutical Industries Ltd.
    10 Mar 2025
    1594.50
    0.55%
    Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics for $355 million; shares edge higher
    Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics for $355 million; shares edge higher
    livemint
    Sun Pharma has acquired Checkpoint Therapeutics for $355 million, enhancing its onco-dermatology portfolio with the FDA-approved drug UNLOXCYT. The deal, expected to close in 2025, reflects Sun Pharma's strategy to strengthen its oncology presence and improve patient access to innovative treatments.
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical Industries Ltd. is trading below all available SMAs
    Sun Pharma to acquire US based onco-derma firm Checkpoint for $355 mn
    Business Standard | 10 Mar 2025 3 more
    Sun Pharma to acquire Checkpoint Therapeutics Inc, for a consideration of upto $355 million
    Business Line | 10 Mar 2025
    Sun Pharma to acquire US based Checkpoint Therapeutics for $355 million
    Business Standard | 10 Mar 2025
    Sun Pharma To Acquire US Cancer Treatment Provider Checkpoint Therapeutics For Rs 3,084 Crore
    NDTV Profit | 10 Mar 2025
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd